The Biden Administration versus Medicare Advantage

21 February 2024 - When does the failure to answer a phone call in 8 seconds cost the company receiving the ...

Read more →

Health Canada approves Brukinsa (zanubrutinib) for the treatment of relapsed or refractory follicular lymphoma

7 February 2024 - Brukinsa is the first and only BTK inhibitor approved for follicular lymphoma in Canada. ...

Read more →

PHARMAC to fully fund testosterone gel for all who need it

8 February 2024 - PHARMAC is funding testosterone gel without restrictions as an additional testosterone treatment for anyone who needs ...

Read more →

Knight Therapeutics announces launch of Bijuva in Canada

6 February 2024 - Knight Therapeutics announced today the launch of Bijuva (oestradiol and progesterone) capsules in Canada. ...

Read more →

HLS announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan

6 February 2024 - Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, ...

Read more →

Rhythm Pharmaceuticals announces positive reimbursement decision in Italy for Imcivree (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl syndrome

7 February 2024 - Rhythm Pharmaceuticals today announced that the Italian Medicine Agency (AIFA) approved reimbursement (Gazzetta Ufficiale) for Imcivree (setmelanotide) ...

Read more →

Bristol Myers Squibb announces acceptance of US and EU regulatory filings for neo-adjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo in resectable non-small cell lung cancer

7 February 2024 - Applications based on results from CheckMate-77T, the company’s second positive Phase 3 randomised trial with an immunotherapy-based ...

Read more →

FDA and EMA launch parallel scientific advice pilot program for complex generics

7 February 2024 - CDER’s Office of Generic Drugs and the EMA launched a voluntary pilot program to facilitate concurrent discussions ...

Read more →

FDA grants latozinemab breakthrough therapy designation for frontotemporal dementia due to a progranulin gene mutation

7 February 2024 - Latozinemab is the most advanced progranulin-elevating candidate in development for frontotemporal dementia with a progranulin gene mutation ...

Read more →

Olaparib in combination with abiraterone acetate for the treatment of patients with hormone relapsed metastatic prostate cancer

7 February 2024 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) in combination with abiraterone ...

Read more →

Nivolumab with relatlimab for the treatment of patients with unresectable or metastatic melanoma

7 February 2024 - NICE has published final evidence-based recommendations on the use of nivolumab with relatlimab (Opdualag) for the ...

Read more →

Belumosudil mesylate for the treatment of patients with chronic graft versus host disease

7 February 2024 - NICE has published final evidence-based recommendations on the use of belumosudil mesylate (Rezurock) for the treatment ...

Read more →

GSK’s RSV vaccine, Arexvy, accepted under priority review in US for the prevention of RSV disease in adults aged 50-59 at increased risk

6 February 2024 - Application supported by positive results of a Phase 3 trial showing immune response and acceptable tolerability profile ...

Read more →

Updates to the HTA Review: consultation 2 survey

6 February 2024 - Access to the HTA Review Consultation 2 online survey is now available on the Office of ...

Read more →

Arvinas and Pfizer’s vepdegestrant (ARV-471) receives FDA fast track designation for the treatment of patients with ER positive/HER2 negative metastatic breast cancer

6 February 2024 - Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the ...

Read more →

Chiesi Global Rare Diseases announces Health Canada approval of Myalepta (metreleptin for injection) for the treatment of patients with lipodystrophy

5 February 2024 - Canadian patients living with this ultra-rare condition welcome this new treatment option. ...

Read more →